CASI Pharmaceuticals, Inc.
BEIJING, F4 · Founded 2023 · CIK 0001962738 · Biotech · Public
Innovative biopharmaceutical therapeutics and pharmaceutical products
casipharmaceuticals.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $35M
- 5 Form D · Apr 2026
- 5 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 3 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $15,000,000 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $5,000,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $5,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2127 | SENSORIUM THERAPEUTICS INC | — | $39M |
| 2128 | CMTX BIOTECH INC | — | $500K |
| 2129 | ProMIS Neurosciences Inc. | — | $39M |
| 2130 | CASI Pharmaceuticals, Inc. | — | $35M |
| 2131 | BLUE THERAPEUTICS, INC. | — | — |
| 2132 | ProteoPrinceps, LLC | — | — |
| 2133 | Rebiotix Inc. | — | $29M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David CoryDirector · Executive Officer
- Thomas FolinsbeeDirector
- Wei GaoExecutive Officer
- Wei-Wu HeDirector · Executive Officer
- Hai HuangExecutive Officer
- James HuangDirector
- Barbara Krebs-PohlDirector
- Kun QianExecutive Officer
- Zhenbo SuDirector
- Chunhua WangExecutive Officer
- Alexander WuDirector
- Xuebo ZengDirector
- Wei (Larry) ZhangExecutive Officer
- Alexander ZukiwskiExecutive Officer
Patents
- CRYSTALLINE FORMS AND FORMULATIONS OF A VCP/p97 INHIBITORgranted
- Methods Of Blood Screeningapplication
- VCP/p97 INHIBITOR FOR THE TREATMENT OF CANCERapplication
- Methods Of Blood Screeninggranted
- VCP/p97 INHIBITOR FOR THE TREATMENT OF CANCERapplication
- Method for the Treatment of Multiple Sclerosisgranted
- Methods Of Blood Screeningapplication
- Methods Of Blood Screeningapplication
- VCP/P97 Inhibitor For The Treatment Of Cancerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.